Gilead Continues Oncology Spree with US$2.2 B Arcus Deal
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 6 (Table of Contents)
Published: 3 Jun-2020
DOI: 10.3833/pdr.v2020.i6.2541 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to build on its growing immuno-oncology presence, Gilead Sciences has formed a 10-year partnership with Arcus Biosciences to jointly develop and commercialise all current and future therapeutic product candidates in Arcus’s pipeline in exchange for US$375 M upfront...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS